Understanding the Hemodialysis Procedure

Hemodialysis is a life-saving medical procedure used to treat patients with kidney failure. When the kidneys can no longer function properly, they are unable to filter toxins and excess fluids from the blood. Hemodialysis steps in to perform this vital function, helping maintain balance in the body and prolong life.

How It Works

The process of hemodialysis involves diverting the patient's blood through a machine called a dialyzer, often referred to as an "artificial kidney." This machine cleans the blood by removing waste products and excess fluids, then returns the filtered blood back into the patient's body.

Blood is drawn from the patient through a vascular access point, typically created surgically in the arm. The blood flows through the dialyzer, where it is filtered by a semipermeable membrane. A special dialysate solution on the other side of the membrane helps draw out unwanted substances, allowing the clean blood to be returned.

Frequency and Duration

Hemodialysis is usually performed several times a week, with each session lasting around four hours. The frequency and duration may vary depending on the patient's medical condition and the type of dialysis treatment they are receiving.

Impact on Lifestyle

While hemodialysis significantly improves the quality of life for patients with kidney failure, it requires a substantial commitment in terms of time and lifestyle adjustments. Patients often need to adhere to a strict diet and fluid intake restrictions to manage their condition between treatments.

Advancements in Hemodialysis

Recent advancements in technology have improved the efficiency and comfort of hemodialysis, with options like home dialysis offering greater flexibility for patients. Despite these improvements, hemodialysis remains a critical procedure for many individuals with end-stage renal disease, helping them live longer and healthier lives.

Image-Guided Radiation Therapy Market Valuation to Climb to $2.4 Billion by 2028

 The Image-Guided Radiation Therapy Market Forecast shows significant growth due to advancements in healthcare infrastructure, increasing cancer prevalence, and favorable reimbursement policies. Key technological innovations, regulatory frameworks, and the rising adoption of minimally invasive procedures further support market expansion, although competition from alternative treatments like IMRT could constrain growth.

The report Image-Guided Radiation Therapy Market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171554723

Market Segmentation: -

PET/ MRI-guided radiation therapy segment to register a significant growth rate over the forecast period of 2022-2028.

Based on the product, the image-guided radiation therapy market is segmented into LINAC (linear accelerator), 4D gating/ 4D RT, PET/ MRI-guided radiation therapy, CT scanning, and portal imaging. The capability of PET/MRI to furnish functional insights directs the administration of radiation doses, effectively mitigating healthy tissue exposure and subsequently alleviating the occurrence of adverse effects. This contribution significantly bolsters the market trajectory of image-guided radiation therapy, enhancing its appeal and positioning within the healthcare landscape.

The breast cancer application segment accounted for a significant share of the image-guided radiation therapy market in 2022-2028.

Based on the application, the image-guided radiation therapy market is segmented into breast cancer, prostate cancer, head & neck cancer, lung cancer, gastrointestinal cancer, gynecological cancer, and other applications. The rising incidence of cancer worldwide is a significant driver for the image-guided radiation therapy market. The precision inherent in image-guided radiation therapy (IGRT) mitigates the necessity for frequent and discomforting repositioning of patients during treatment sessions.

 

Intensity modulation radiation therapy procedure segment accounted for the largest share of the image-guided radiation therapy market in 2022-2028.

Based on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, stereotactic therapy, proton beam therapy, intensity modulation radiation therapy,  and particle therapy. The intensity modulation radiation therapy procedure segment is estimated to hold the 39.2%  market share of the image-guided radiation therapy market in 2022. Intensity Modulated Radiation Therapy (IMRT) is instrumental in crafting tailored treatment blueprints through the optimization of radiation administration based on tumor dimensions, contours, and placement. This congruence aligns seamlessly with the personalized treatment ethos central to Image-Guided Radiation Therapy (IGRT).

Hospitals segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.

The major end users in the image-guided radiation therapy market are independent radiotherapy centers and hospitals. Hospitals are expected to account for a major market share in 2022. Healthcare institutions grapple with a considerable influx of cancer patients, thereby magnifying the attraction towards image-guided radiation therapy (IGRT). The precision inherent in IGRT's tumor-targeting proficiency and its streamlined treatment delivery harmonize seamlessly with the necessity of proficiently managing the patient caseload.

Regional Analysis:-

In 2022, the North American region is expected to register significant growth in the market during the forecast period. North America comprises the US and Canada. North America has an advanced healthcare infrastructure, which is associated with a higher incidence of cancer. In North America, a highly developed healthcare infrastructure coupled with ready access to state-of-the-art medical technologies creates a conducive environment for the assimilation of progressive treatment modalities, such as image-guided radiation therapy (IGRT).

Key Players:-

As of 2022, prominent players in the image-guided radiation therapy market are Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Recent developments

Recent developments, such as Philips' Zenition 10, GE HealthCare's advances in PET/MR capabilities, and the launch of Pixxoscan, highlight the industry's commitment to advancing cancer care.

Conclusion

Image-Guided Radiation Therapy is revolutionizing cancer treatment by offering precise, patient-centric care. As a medical industry expert, I'm thrilled to witness this transformation. With continued advancements, a supportive healthcare ecosystem, and a global focus on non-invasive cancer interventions, IGRT is set to play a pivotal role in shaping the future of cancer treatment worldwide. As the industry embraces innovation, research, and collaboration, the promise of improved cancer outcomes becomes increasingly achievable.

Content Source: -

Image-Guided Radiation Therapy Market Report

Image-Guided Radiation Therapy Market Press Release

An Overview of Long-Read Sequencing Technology

Long-read sequencing, also known as third-generation sequencing, is a cutting-edge technology in genomics that offers significant advantages over traditional short-read sequencing. Long-Read Sequencing Technology is characterized by its ability to generate much longer DNA or RNA sequences, providing a more comprehensive view of the genome.

Key Technologies

Two major platforms dominate the long-read sequencing market:

1. Pacific Biosciences (PacBio): PacBio’s Single-Molecule Real-Time (SMRT) sequencing technology reads long stretches of DNA by tracking the incorporation of nucleotides in real-time. This method produces high-accuracy long reads, known as HiFi reads, which can reach up to 20,000 base pairs in length, enabling detailed genome assemblies and variant detection.

2. Oxford Nanopore Technologies: Oxford Nanopore’s sequencing technology passes DNA or RNA molecules through nanopores, generating ultra-long reads in real-time. This platform allows sequencing of entire chromosomes in one read, making it highly flexible and capable of reading even extremely long DNA sequences of up to millions of base pairs.

Advantages of Long-Read Sequencing Technology

• Longer Read Lengths: Long-read sequencing can generate reads ranging from several kilobases to even megabases, providing better resolution for complex regions of the genome, including structural variants and repetitive sequences.

• Real-Time Data: Both PacBio and Oxford Nanopore provide real-time sequencing data, enabling rapid insights into genomic data without waiting for the entire sequencing run to complete.

• De Novo Genome Assembly: Long-read sequencing is ideal for assembling genomes from scratch, providing a more complete and accurate assembly by bridging gaps left by short-read technologies.

• Epigenetic Information: Nanopore sequencing can also detect epigenetic modifications, such as DNA methylation, without additional chemical treatments, offering insights into gene regulation mechanisms.

Applications

Long-read sequencing technology has transformative applications in various fields, including:

• Human Genomics: It improves the detection of structural variants and complex genetic regions, aiding in the study of diseases and personalized medicine.
• Agrigenomics: In plant and animal genomics, long-read sequencing helps in the accurate assembly of complex genomes, leading to advances in agriculture and conservation.
• Microbial Genomics: Long-read sequencing is crucial in microbial studies for resolving complete genomes and studying antibiotic resistance genes.

In conclusion, long-read sequencing technology represents a significant leap forward in genomics, offering more accurate, detailed, and comprehensive genetic information. It is poised to revolutionize research in many areas, from human health to biodiversity.

Hemodialysis and Peritoneal Dialysis Market Expected to Grow to $126.2 Billion by 2029

 The rising global incidence of chronic kidney disease (CKD) is anticipated to fuel the hemodialysis and peritoneal dialysis market forecast. More than 10% of the global population is expected to be affected by CKD due to factors such as an aging population, increasing diabetes and hypertension rates, which accelerate CKD progression to end-stage renal disease, requiring dialysis. CKD is most common among individuals aged 65 and older. In 2023, the CDC estimated that 35.5 million people in the U.S. were diagnosed with CKD.

The report Hemodialysis and Peritoneal Dialysis Market is projected to reach USD 126.2 billion by 2029 from USD 92.0 billion in 2024 at a CAGR of 6.5% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279
 
Browse

• 150    Market Data Tables
• 65       Figures
• 350     Pages and in-depth TOC on " Hemodialysis and Peritoneal Dialysis Market - Global Forecast to 2029”

Some of the prominent key players are:

• Fresenius Medical Care AG & Co. KGaA (Germany),
• Baxter International Inc. (US),
• Nipro Corporation (Japan),
• NIKKISO CO., LTD. (Japan),  and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Hemodialysis and Peritoneal Dialysis Market.

Opportunity: High growth potential of emerging markets

Emerging markets such as China, India, Brazil, are expected to offer significant growth opportunities for players operating in the POC diagnostics market. This is primarily due to the high and growing prevalence of diabetes, chronic kidney diseases, in these countries. As economic growth in China and India continues to expand, there is rise in healthcare spending across these countries, which leads to improved affordability of hemodialysis and peritoneal dialysis treatment. According to the article published by BMC Nephrology in 2023, in China, the prevalence of ESRD is projected to reach 1,505 patients per million population by 2025. To meet the increasing demand for dialysis in the emerging markets, players focus on acquiring or entering into agreements and partnerships with healthcare providers.

Market Segmentation: -

• The hemodialysis market is segmented based on product and service. Hemodialysis products include hemodialysis machines and hemodialysis consumables & supplies, whereas hemodialysis services include in-center services and home services. The hemodialysis services segment is anticipated to grow at significant rate during the forecast period.
• Based on end users, home care setting is expected to grow at a significant rate owing to growing preference of patients for home hemodialysis modality, technological advancements, and the cost-effectiveness of home dialysis treatment over incentre dialysis procedures.
• On the basis of region, the hemodialysis and peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, and the Latin America, Middle East & Africa. The Asia-Pacific market is likely to witness significant market growth. This is attributed to the rise in geriatric patient population, increasing cases of chronic kidney diseases, moreover improving healthcare infrastructure and the implementation of supportive government initiatives to increase the accessibility of dialysis services in many APAC countries such as India and China.

Recent Developments of Hemodialysis and Peritoneal Dialysis Industry:

• In July 2023, Rockwell Medical acquired the hemodialysis concentrates business from Evoqua Water Technologies, strengthening its presence in the hemodialysis market
• In January 2022, Nextkidney BV acquired Dialyss Pte Ltd, enhancing its technology capabilities in home hemodialysis
• In March 2021, DaVita Inc. signed an agreement with Fresenius Medical Care AG & Co. KGaA for the expansion of the usage of NxStage Home Hemodialysis Machines

The escalating global prevalence of chronic kidney disease, spurred by growing aging population coupled with the increasing cases of diabetes and hypertension are fuelling the demand for renal replacement therapy including hemodialysis and peritoneal dialysis products and services. Ongoing technological advancements in dialysis technology, growing patient preference of home dialysis, supporting reimbursement policies and government initiatives and funding for healthcare infrastructure, enabling expansion of hospitals and dialysis centers further enhancing the accessibility of hemodialysis and peritoneal dialysis services among patients with end-stage renal disease (ESRD) are likely to drive the market growth during the forecast period.

Content Source: -

Hemodialysis and Peritoneal Dialysis Market Report

Hemodialysis and Peritoneal Dialysis Market Press Release

 

Operative Techniques: Enhancing Precision in Modern Surgery

Operative techniques, the cornerstone of modern surgery, encompass the various methods and approaches used by surgeons to perform procedures. These techniques have evolved significantly with advances in technology and medical research, leading to improved patient outcomes and shorter recovery times.

From traditional open surgeries to minimally invasive methods such as laparoscopy and robotic-assisted surgeries, operative techniques have broadened the scope of what can be treated surgically. The focus of these advancements is to maximize precision while minimizing trauma to the patient. Minimally invasive techniques, for example, utilize small incisions, reducing the risk of infection and allowing for quicker recovery periods.

In addition to improving the mechanics of surgery, operative techniques now integrate cutting-edge technology like imaging guidance, lasers, and AI-assisted tools, which enable surgeons to perform highly complex procedures with greater accuracy. This evolution is particularly vital in specialized fields such as neurosurgery, cardiovascular surgery, and orthopedic surgery, where precision is paramount.

The ongoing development in operative techniques continues to push the boundaries of medical science, offering new possibilities for treating a wide array of conditions and enhancing the overall effectiveness of surgical interventions.

Global Long-Read Sequencing Market to Achieve $3.1 Billion by 2029

 The long read sequencing market forecast is influenced by rapid technological progress in third-generation sequencing and the increasing incidence of genetic and rare diseases. AI plays a pivotal role in the sequencing process by enhancing data analysis speed and accuracy.

The report Long-Read Sequencing Market is expected to reach USD 3,129 million in 2029 from USD 758 million in 2024, at a CAGR of 32.8% during the forecast period.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140422082
 
Browse

·         398     Market Data Tables

·         60       Figures

·         306     Pages and in-depth TOC on " Long-Read Sequencing Market - Global Forecast to 2029”

Some of the prominent key players are:

·         Oxford Nanopore Technologies plc. (UK),

·         PacBio (US),

·         Illumina, Inc. (US),

·         Agilent Technologies, Inc. (US),

·         Thermo Fisher Scientific Inc. (US),

·         10X Genomics, Inc. (US) and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Long-Read Sequencing Market.

DRIVER: Technological Advancement in genome sequencing

Dealing with the constraints of short-read sequencing technology, long-read sequencing has grown important. The long-read sequencing has revealed numerous underappreciated genomic characteristics including structural variations and repetition arrays. Long-read sequencing enables investigation of previously unreported genomic areas that were challenging to research, and helps investigators to grasp the whole spectrum of human genetic variation. Single-molecule real-time sequencing and nanopore-based sequencing are the two primary forms of long-read sequencing technology. Developed by PacBio (US). High-fi sequencing represents an advancement in SMRT sequencing with an accuracy approaching 99.99%, HiFi sequencing provides sequence lengths of 10–20 kilobase pairs (kbp). This development has facilitated the identification of structural variants and enabled the decoding of acrocentric short arms and centromeres, two repeating sequences of the genome.

OPPORTUNITY: Rising demand for long-read sequencing in clinical genomics

By allowing the identification of a wide spectrum of genetic variants and fusion events, especially in illnesses like cancer, long-read sequencing technology holds great potential in clinical genomics. Long-read sequencing, unlike conventional short-read sequencing, can run in real-time, therefore removing the requirement to batch samples. In urgent clinical conditions and for employing fresh or fresh frozen samples, this capacity is especially helpful. Long-read sequencing shines in detecting important gene fusion events guiding therapy decisions in cancer diagnosis. In chronic myeloid leukemia, for instance, Long-read sequencing finds the BCR-ABL fusion protein—essential for focused treatments. More sensitive than short-read sequencing techniques, long-read sequencing can identify structural variants linked to treatment resistance, therefore enhancing the accuracy of illness diagnosis and therapy monitoring.

Market Segmentation: -

·         By offerings, the long-read sequencing market is segmented into consumables, instruments, and services. The consumables segment accounted for the largest share of the long-read sequencing market in 2023. The large share of the consumables segment can be attributed to the rising demand for genome sequencing, which is driving the consumption of consumables for sequencing.

·         By technology, the long-read sequencing market is segmented into nanopore sequencing, single-molecule real-time sequencing, and synthetic long-read sequencing. The nanopore sequencing segment accounted for the largest share of the long-read sequencing market in 2023.

·         By workflow, the long-read sequencing market is segmented into sequencing, sample preparation, and data analysis. The sequencing segment accounted for the largest share in 2023. The sequencing segment accounted for the largest share, as sequencing forms the largest part of the workflow of the long-read sequencing market.

·         By Application, the long-read sequencing market is segmented into whole genome sequencing, targeted sequencing, metagenomics, epigenetics, whole exome sequencing, and other applications. In 2023, the whole genome sequencing segment accounted for the largest share of the long-read sequencing market.

·         By usage, the long-read sequencing market is segmented into research and clinical. The research segment accounted for the largest share of the long-read sequencing market in 2023. 

·         The long-read sequencing market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest regional market for long-read sequencing in 2023, while Europe is the second-largest market. 

Recent Developments of Long Read Sequencing Industry.

·         In May 2024, Oxford Nanopore Technologies collaborated with Twist Bioscience to launch a new Pharmacogenomics Beta Programme. This long-read pharmacogenomics solution, available for research use, is designed to provide clear genetic results in a single end-to-end workflow from sample to pharmacogenomics star allele call.

·         In September 2023, PacBio announced a partnership with Hamilton, Integra, Revvity, and Tecan to create fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

·         In March 2023, Illumina Inc. launched its first product based on its novel Illumina Complete Long Read technology. The high-performance, long-read, human whole-genome sequencing assay – Illumina Complete Long Read Prep, Human – is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.

Growth in the long-read sequencing market is mainly driven by the increased demand for whole genome sequencing backed by human genome projects. The rising awareness of genome sequencing in disease diagnosis and treatment is also supporting the market growth. Further, the technological advancements in genome sequencing like increased accuracy and read lengths are driving the growth. However, the high-cost investments to develop long-read sequencing technologies are the major factors expected to restrain the growth of this market to a certain extent.

Content Source: -

Long-Read Sequencing Market Report

Long-Read Sequencing Market Press Release

Organ-on-Chip Microfluidics: Revolutionizing Biomedical Research

Organ-on-chip microfluidics is an emerging technology that combines microengineering and biology to simulate the functions of human organs on a chip-sized platform. This innovative approach uses microfluidic devices to create a controlled, miniaturized environment, allowing researchers to replicate the physical and chemical conditions of living tissues. By integrating cell culture with microfluidic channels, organ-on-chip devices can mimic complex biological processes such as blood flow, nutrient exchange, and mechanical forces.

One of the primary benefits of organ-on-chip microfluidics is its potential to revolutionize drug testing and disease modeling. Traditional methods rely heavily on animal models, which often fail to accurately predict human responses. With organ-on-chip technology, researchers can model human organ function more precisely, leading to better drug efficacy testing and a deeper understanding of disease mechanisms. These chips can replicate various organs, such as the liver, heart, lungs, and even the blood-brain barrier, enabling more accurate and personalized research.

Furthermore, organ-on-chip microfluidics holds promise for reducing the need for animal testing and accelerating the development of new treatments. This technology allows for high-throughput screening of drugs in a more ethical and cost-effective manner. As the field advances, it could pave the way for breakthroughs in personalized medicine, where treatments are tailored to the specific needs of individual patients.

Overall, organ-on-chip microfluidics represents a cutting-edge tool in biomedical research, offering a more realistic, scalable, and efficient way to study human biology and disease.

Amniotic Products Market Valuation Projected to Climb to $1,289 Million by 2028

Increased awareness efforts in wound care treatment, combined with venture capital and government investments, are key contributors to the Amniotic Products Market Forecast. However, the market’s growth may be hindered by competing alternative therapies.

The report Amniotic Products Market is projected to reach USD 1,289 million by 2028 from USD 900 million in 2023, at a CAGR of 7.4% during the forecast period.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976

Growth DRIVER: Growth in the target patient population

Physical health conditions, such as chronic diseases, have a negative effect on the wound healing process. For instance, diabetes and obesity can result in an increased incidence of ulcerations, such as leg or foot ulcers, which would require wound treatment and incur exorbitant medical expenses.

As per the IDF 2021, 537 million adults (20-79 years) are living with diabetes (1 in 10). This number is estimated to rise to 643 million by 2030 and 783 million by 2045. Diabetic foot ulcers occur because of major complications of diabetes. Nearly 15% of the total diabetic population suffers from diabetic foot ulcers (Source: Cellular and Molecular Basis of Wound Healing in Diabetes by Brem H., Journal of Clinical Investigation). An article published in the Journal of Foot and Ankle Research estimates that more than 10% of people with type 2 diabetes mellitus are highly prone to foot ulcers, with a lifetime risk of 15%. 

Growth OPPORTUNITY: Emerging economies

Emerging countries such as China, India, South Korea, Brazil, and Mexico offer significant growth opportunities to major players functioning in the amniotic products industry. This can be attributed to low regulatory barriers, improvements in healthcare infrastructure, growing patient population, and rising healthcare expenditure. Moreover, regulatory policies in the Asia Pacific region are more adaptive and business-friendly in comparison to those of developed countries. This factor, in addition to the increasing competition in mature markets, has drawn key players in the market to focus on the emerging economies.

 

Market Segmentation: -

The Europe amniotic products market is segmented into Germany, France, the UK, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the high prevalence of diabetes and venous ulcers in the UK, increasing R&D activities, strategic developments by key players, and the growing geriatric population.

Based on the end user, the amniotic products market is segmented into Hospitals, & Ambulatory Surgical Centers, and Other End Users. The Hospitals, & Ambulatory Surgical Centers registered the highest CAGR, increasing hospital admissions due to chronic wounds (such as pressure and diabetic foot & venous leg ulcers) and the rising incidence of hospital-acquired pressure ulcers are key drivers for the growth of this end-user segment.

Regional Analysis:

The APAC amniotic products market is segmented into Japan, China, and Rest of Apac. In 2022, China accounted for the largest share of the Asian amniotic products market. The large share of China can be attributed to the economic growth in the country, rising incidence of diabetes, significantly high cases of road accidents, increasing disposable income of the middle-class population, growth in the geriatric population, and favourable government support.

Recession Impact on the Amniotic Products Market

The impact of a global recession can vary across different regions and countries. Economic conditions, healthcare systems, and regulatory environments differ worldwide, and the severity and duration of the recession will also influence the extent of its impact on the amniotic membranes market globally. During a global recession, the amniotic membranes market could experience several potential impacts. 

Recent Developments of Amniotic Products Industry

• In 2021, The company VIVEX Biologics (US) launched Cygnus Matrix Disks with the latest configuration of the Cygnus family of amniotic tissue allografts.
• In 2021, MiMedx (US) received approval from the Japanese Ministry of Health, Labour, and Welfare for the commercialization of EPIFIX in Japan.
• In 2021, The company Celularity Inc. (US) entered into an exclusive distribution agreement for the commercial distribution rights for orthopedic surgery and sports medicine products with Arthrex, Inc. (US).

Top Key Players:

The significant players in the amniotic products market are mimedx (US), Smith+Nephew (UK), Organogenesis Inc. (US), Integra LifeSciences (US), Stryker (US), APPLIED BIOLOGICS. (US), Celularity Inc. (US), Corza Ophthalmology (US), Lucina BioSciences (US), and Next Biosciences. (South Africa).

Conclusion:

The Amniotic Products Industry is poised for substantial growth, driven by increasing awareness, investments, and the need for innovative solutions in wound care and regenerative medicine. As we move forward, it will be exciting to witness how this industry continues to evolve and contribute to improving patient outcomes worldwide.

Content Source: -

Amniotic Products Market Report
Amniotic Products Market Press Release
Amniotic Products Market PRNewswire

 

Pharmaceutical Filtration Equipment: Ensuring Purity and Safety in Drug Manufacturing

 Pharmaceutical filtration equipment plays a crucial role in ensuring the purity, safety, and quality of drugs during the manufacturing process. This equipment is used to remove contaminants, such as particulates, bacteria, and other impurities, from raw materials, intermediates, and final drug products. Filtration is an essential step in the production of pharmaceuticals, ensuring that the end products meet stringent regulatory standards and are safe for patient use.

Key Types of Pharmaceutical Filtration Equipment

1. Membrane Filters: These are widely used in the pharmaceutical industry for sterilization and microbial removal. Membrane filters allow fluids to pass through while blocking contaminants, ensuring that the final product is free of unwanted particles.

2. Depth Filters: Depth filtration involves trapping contaminants within the filter matrix rather than on the surface. This type of filtration is useful for handling large volumes of liquids and removing a high load of particulates.

3. Cartridge Filters: Cartridge filters are cylindrical in shape and used in a wide range of applications, including pre-filtration and final filtration processes. They are known for their efficiency and ease of replacement.

4. Ultrafiltration Systems: These systems are used for separating large molecules, such as proteins, from smaller ones. Ultrafiltration is commonly used in the production of biologics and other complex pharmaceutical products.

5. Nanofiltration and Reverse Osmosis Systems: These advanced filtration systems are used to purify water, which is a critical component in pharmaceutical manufacturing. Nanofiltration and reverse osmosis help remove dissolved salts, organic compounds, and other impurities from water.

Importance of Pharmaceutical Filtration

• Ensuring Drug Safety: Filtration is vital for removing contaminants that could compromise the safety of pharmaceuticals. Ensuring that drugs are free from harmful particles, bacteria, and viruses is essential for patient safety.

• Compliance with Regulations: The pharmaceutical industry is highly regulated, and filtration helps manufacturers comply with strict quality standards set by organizations like the FDA and EMA.

• Enhancing Product Quality: High-quality filtration processes ensure that drugs are pure and effective, which is critical for maintaining the reputation and reliability of pharmaceutical brands.

Market Outlook

The demand for pharmaceutical filtration equipment is growing as the industry continues to expand and adopt advanced manufacturing processes. The rise of biologics, personalized medicine, and stringent regulatory requirements are driving the need for innovative and efficient filtration technologies. As pharmaceutical companies strive to meet these demands, investment in state-of-the-art filtration equipment is expected to increase.

Pharmaceutical filtration equipment is not just a crucial part of drug manufacturing; it is a key component in safeguarding public health and ensuring that medicines are both safe and effective.

Theranostics Market Forecast to Grow to $4.3 Billion by 2028

 According to the Theranostics Market Forecast, growth is being driven by the rising number of cancer cases and the growing use of radiopharmaceuticals in neurological applications. Emerging markets offer opportunities due to an increase in targeted diseases and hospital expansions.

The report Theranostics Market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028.

 
Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111696976
 

Growth Drivers

 

Precision medicine or personalized medicine involves the targeted approach for a patient by considering the difference in the genes and other factors such as lifestyles and environments. Specific characteristics of a patient are analyzed tailored for innovative approach to medical treatment. The treatment or therapy designed for the patient by considering the molecular and cellular profile results in effective prevention, diagnosis, improved outcomes, and reduced side effects.

Market Segmentation: -

• Based on the product, the global theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/Biomarker screening, and software and services. The radiopharmaceuticals segment is anticipated to register the highest growth rate over the forecast period and also accounted for the highest share of the theranostics market in 2022.
• Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer segment accounted for the largest share of the market in 2022 and is also expected to grow at the highest CAGR during the forecast period.
• Based on end user, the global theranositcs market is segmented into hospitals and cancer centers, theranostics centers, and research and academic centers. The hospitals and cancer care centers segment accounted for the largest share of the market in 2022. Consistent rise in the number of hospitals and rising old-age population are driving the growth of this segment.
• The Asia Pacific theranostics market is anticipated to register the highest growth from 2023 to 2028. The key players of theranostics market are focusing on expanding their footprint in the APAC region. This region is witnessing a significant rise in the adoption of the treatment by different end user facilities in the region.

Growth opportunities 

Developing economies such as offer growth opportunities for the major players in the market. Although the cost factor is a concern in these developing countries, their huge population base—especially in India and China—offers a sustainable market for theranostics.

The high incidence of chronic diseases such as cancer, strokes, and neurological and cardiovascular diseases, as well as the high death rates in these countries, have increased the need for early detection. According to a GLOBOCAN 2020 report, the number of new cancer cases diagnosed in 2020 was 19.3 million, and almost 10.0 million died due to cancer.

Recent Developments of Theranostics Industry:

• Advanced Accelerator Applications (France) received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Pluvicto is a targeted radioligand therapy for patients with prostate cancer with a therapeutic radioisotope.
• Bayer AG (Germany) and the Broad Institute of MIT and Harvard (US) extended their long term collaboration for the advancement of new therapeutic approaches in cancer.
• GE Healthcare collaborated with the Mayo Clinic (US) for innovation in research and product development. The collaboration aims to have the technology for clinicians for the precise diagnosis and approaches to theranostics and medical imaging.

Top Key Players:

As of 2022, prominent players in the market are Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period. Introduction of artificial intelligence (AI) helps to improve the diagnostic accuracy. Recent FDA approvals increases the awareness and supports rising adoption of theranostics.

 

Content Source:

Theranostics Market Report

Theranostics Market Press Release

Theranostics Market PRnewswire